Join the Breast Cancer group to help and get support from people like you.
Breast Cancer News (Page 13)
Related terms: Breast Cancer, inflammatory, Cancer, Breast, Carcinoma, Ductal, Carcinoma, Lobular, Ductal Carcinoma in Situ (DCIS), Ductal Carcinoma in Situ, DCIS
Adherence to Global Health Recommendations Cuts Risk for Some Cancers
TUESDAY, July 18, 2023 – Greater adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations is associated with a lower risk for breast,...
Models Can Predict Breast Cancer-Related Lymphedema
FRIDAY, July 14, 2023 – Preoperative and postoperative models are highly accurate for predicting breast cancer-related lymphedema (BCRL), according to a study published online July 12 in JAMA...
More Cancer Patients Got Palliative Care After Obamacare
THURSDAY, July 6, 2023 – New research finds that Medicaid expansion under the Affordable Care Act – also known as Obamacare – brought an unexpected benefit: increases in how many patients got...
Staying Fit Lowers a Man's Cancer Risk, Study Confirms
MONDAY, July 3, 2023 – A man’s cardio fitness might influence whether he’ll develop – or survive – three of the most common cancers in males, a new Swedish study reports. Higher levels of cardio fi...
FDA Broadens Indication for Verzenio (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
INDIANAPOLIS, March 3, 2023 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio...
U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer
First Trop-2 Directed ADC to Demonstrate Overall Survival Benefit in HR+/HER2- Metastatic Breast Cancer Patients who had Received Prior Endocrine-based Therapy and at Least Two Chemotherapies...
FDA Approves Orserdu (elacestrant) for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been...
Enhertu Approved in the US as the First HER2-Directed Therapy for Patients with HER2-Low Metastatic Breast Cancer
Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reduced risk of disease progression or death by 50% and increased overall survival by more than six months v...
Enhertu Approved in the US for Patients with HER2-Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Approval broadens indication for AstraZeneca and Daiichi Sankyo’s Enhertu to earlier use in metastatic breast cancer Based on ground-breaking DESTINY-Breast03 results showing Enhertu reduced the r...
Lynparza Approved in the US as Adjuvant Treatment for Patients with Germline BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
First and only approved medicine targeting BRCA mutations in early breast cancer New data show Lynparza demonstrated overall survival benefit in early breast cancer March 11, 2022 – A...
FDA Approves Verzenio (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
INDIANAPOLIS, Oct. 13, 2021 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with endocrine ...
FDA Approves Keytruda (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
KENILWORTH, N.J.--(BUSINESS WIRE) July 27, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Trodelvy, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 7, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Tro...
FDA Approves Margenza (margetuximab-cmkb) for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
ROCKVILLE, MD, Dec. 16, 2020 (GLOBE NEWSWIRE) – MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based ...
FDA Approves Merck’s Keytruda (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
KENILWORTH, N.J.--(BUSINESS WIRE) November 13, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Cancer
Related drug support groups
methotrexate, fluorouracil, anastrozole, letrozole, Arimidex, Herceptin, Keytruda, Femara, trastuzumab, tamoxifen, Ibrance